Researcher
Joachim Mertens
- Keywords:Pharmacy and pharmacology
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal chemistry, Medicinal products, Pharmaceutical analysis and quality assurance, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Other medical and health sciences
Affiliations
- Medical Biochemistry (Research group)
Member
From1 Oct 2020 → 30 Sep 2021 - Medical Biochemistry (Research group)
Member
From1 Oct 2015 → 30 Sep 2020
Projects
1 - 2 of 2
- Carboxypeptidase U - a new drug target for the improvement of treatment in acute ischemic stroke.From1 Oct 2018 → 30 Sep 2020Funding: FWO fellowships
- Carboxypeptidase U - a new drug target for the improvement of treatment in acute ischemic stroke.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
Publications
1 - 10 of 10
- Monitoring the SARS-CoV-2 pandemic(2022)
Authors: Joachim Mertens, Jasmine Coppens, Katherine Loens, Marie Le Mercier, Basil Britto Xavier, Sarah Vandamme, Herman Goossens, Veerle Matheeussen
Pages: 124 - 129 - Carboxypeptidase U (TAFIa) is rapidly activated and deactivated following thrombolysis and thrombectomy in stroke patients(2021)
Authors: Joachim Mertens, Vanessa Blanc-Guillemaud, Karen Claesen, Pere Cardona, Benoit Tyl, Carlos A. Molina
- Effect of statin therapy on the carboxypeptidase U (CPU, TAFIa, CPB2) system in patients with hyperlipidemia(2021)
Authors: Karen Claesen, Joachim Mertens, Shahir Basir, Simon De Belder, Jeroen Maes, Johan Bosmans, Hilde Stoffelen, Ingrid De Meester
Pages: 908 - 916 - Carboxypeptidase U (CPU, TAFIa, CPB2) in thromboembolic disease(2021)
Authors: Karen Claesen, Joachim Mertens, Dorien Leenaerts, Dirk Hendriks
- Pleiotropic effects of Atorvastatin result in a downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a mouse model of advanced atherosclerosis(2021)
Authors: Karen Claesen, Lynn Roth, Joachim Mertens, Karlijn Hermans, Yani Sim, Dirk Hendriks
- Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke(2020)
Authors: Joachim Mertens, William Boisseau, Dorien Leenaerts, Lucas Di Meglio, Stéphane Loyau, Célina Ducroux, Martine Jandrot‐Perrus, Jean‐Baptiste Michel, Mikael Mazighi, Jean‐Philippe Desilles
Pages: 3325 - 3335 - The carboxypeptidase U system in acute ischemic stroke(2020)
Authors: Joachim Mertens
Number of pages: 306 - Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis(2019)
Authors: Joachim Mertens, Karen Claesen, Dorien Leenaerts, Yani Sim
Pages: 878 - 884 - Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction(2018)
Authors: Joachim Mertens, Dorien Leenaerts, Raf Brouns, Sebastiaan Engelborghs, Margareta Ieven
Pages: 342 - 348 - Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different invitro models(2018)
Authors: Dorien Leenaerts, S. Loyau, Joachim Mertens, W. Boisseau, J. B. Michel, M. Jandrot-Perrus
Pages: 2057 - 2069